PubMed Health⌕ Search

Biomedical subjects

N Bozorgi

Publications and source records attributed to N Bozorgi.

7 recordsLinked to original sources
PubMed1993

Influence of maternal age, birth-to-conception intervals and prior perinatal factors on perinatal outcomes.

This study evaluated the influence of prior perinatal factors on birth weight, length of gestation, and maternal pregravid and postpartum weights in subsequent pregnancies. The study sample included 47 women each with first, second and third pregnancies. Mean pregravid weight increased by 5.2 lb between the first and second pregnancies and by 4.4 lb between the second and third pregnancies. Total weight gain averaged 31 lb for the first pregnancy and 28.4 and 28.3 lb for the second and third pregnancies, respectively. Mean birth weight increased by 111 g between the first and second pregnancies and by 199 g between the second and third pregnancies. Mean gestational age was similar for all three pregnancies, averaging 39.5 weeks. Using stepwise forward multiple regression analyses, we determined that birth weight and length of gestation are both influenced significantly by prior birth weight and length of gestation; subsequent pregravid weight is influenced significantly by prior rate of gain, pregravid weight and postpartum weight; and postpartum weight is significantly influenced by prior rate of gain and birth weight. Comparisons across three pregnancies for the same woman showed that differences in birth-to-conception interval were not associated with higher postpartum weight or subsequent pregravid weight. These data indicate that in healthy, nonsmoking, low-risk women, the maternal and infant outcomes of pregnancies are significantly influenced by prior outcomes but not by either short birth-to-conception interval or greater maternal age.

Adult↗
PubMed1992

Analyses of 95 first-trimester spontaneous abortions by chorionic villus sampling and karyotype.

PURPOSE: Our purpose was to determine the incidence of chromosomal aneuploidy in first-trimester pregnancy losses using chorionic villus sampling (CVS). STUDY DESIGN: All patients presenting for CVS with no fetal cardiac activity were offered CVS. RESULTS: Cytogenetic results were completed in 95 of 96 cases (99%). Eighty-three percent of the karyotypes were aneuploid. The 16 euploid fetuses had no excess of females. CONCLUSION: CVS is the most reliable method of determining the karyotype of spontaneously aborted fetuses. The incidence of aneuploidy is much greater than in previous reports that analyzed passed products of conception. CVS should be offered to women who present with first-trimester spontaneous abortions.

Abortion, Spontaneous↗
PubMed1992

Decreasing risk of pregnancy loss following chorionic villus sampling. Elimination of transabdominal chorionic villus sampling during the ninth week of pregnancy.

Chorionic villus sampling (CVS) is a method of obtaining fetal cells in the first trimester of pregnancy for genetic analysis. The transcervical (TC) approach was the first technique to be widely used. In the National Institute of Child Health and Human Development collaborative study the absolute loss rate following CVS (the total number of spontaneous abortions and neonatal deaths following CVS) was 4%. More recently the transabdominal (TA) approach has been introduced. This study compares the loss rates for the two approaches at various gestational ages for three 6-month periods following the addition of the TA approach with each other and with the loss rates prior to the introduction of TA CVS. We found that the percentage of pregnancy losses following TA CVS during the ninth week of gestation (63-69 days) was consistently higher than for TC CVS performed at the same gestational age. The loss rate for TC CVS has steadily decreased since the introduction of TA CVS after remaining the same for the two years prior to the introduction of the TA approach. After minimizing the number of TA CVS performed during the ninth week of gestation, the overall loss rate during the most recent 6-month period has been reduced to 0.94%. We conclude that the lowest loss rate following CVS can be obtained if both the TA and TC methods are available, and that the number of TA procedures performed during the ninth week of gestation is minimized.

Abortion, Spontaneous↗
PubMed1978

Reduced dose of Rh immunoglobulin following first trimester pregnancy termination.

The efficacy and safety of a 50-microgram dose of Rh immune globulin for prevention of Rh isosensitization following first trimester vacuum abortion are evaluated in this study. A total of 1027 women undergoing abortion at three outpatient facilities participated in the study; 755 (73.5%) completed follow-up serologic screening 6 months after termination of pregnancy. None showed serologic evidence of Rh sensitization at the time of followup. No serious adverse reactions to the drug were observed.

Abortion, Induced↗
PubMed1977

Statistical analysis of first-trimester pregnancy terminations in an ambulatory surgical center.

From June, 1973, to December, 1974, 12,219 women requested elective termination of pregnancy at the Concord Medical Center, a private outpatient clinic in Chicago, Illinois. Suction curettage with local anesthesia was performed for 10,890 of the women; the remaining 1,329 (10.9%) women were rejected for the following reasons: not pregnant, 1.9%; estimated duration of pregnancy over 12 weeks, 7.3% medical reasons, 1.6%; and other reasons, 0.1%. For the aborted patients, the immediate complication rate was 6.9 per 1,000. Complication rates were directly associated with length of gestation (whether determined on the basis of the patient-reported last menstrual period (LMP) or on the basis of the physical examination) and with the experience of the physicians. This study adds further evidence that first-trimester termination of pregnancy by suction curettage, with local anesthesia, in a nonhospital setting is a safe procedure when high medical standards are maintained.

Abortion, Legal↗
PubMed1977

Small dose anti-Rh therapy after first trimester abortion.

The standard prophylactic dose of anti-Rh immunoglobulin used in the United States is 300 microgram. For use after spontaneous or induced abortion and diagnostic amniocentesis, this dose represents immunological "overkill". A 50 microgram dose has been effectively used for these patients in other countries but the specific products used were not equivalent to the products available in the USA. No evaluation of this 50 microgram dose has been conducted in the USA. This is a pilot study of 315 patients given a 50 microgram dose or a 300 microgram dose of anti-Rh immunoglobulin after first trimester abortion. No patient in either treatment group developed atypical blood group antibodies within 6 months. This finding confirms that 50 microgram of the American product is protective after first trimester abortion.

Abortion, Induced↗